Disclaimer: The following content discusses our Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by our FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath-enabled TAMP with gemcitabine for the treatment of locally advanced pancreatic cancer (LAPC) is being studied under an IND. This combination product candidate has not been approved by FDA for commercial use and its safety and effectiveness in treating LAPC has not been established. For RenovoCath’s Indications for Use and safety information, please visit IFU-10004-Rev.-H-Universal-IFU.pdf.
New Cancer Tech Sends Chemo Straight To Tumors
A targeted drug-delivery device may help some pancreatic cancer patients get chemotherapy with fewer body-wide side effects.
Delivering Chemotherapy Directly to the Tumor: Inside TAMP Technology
CURE recently visited Hackensack Meridian Jersey Shore University Medical Center (JSUMC) to speak with Dr. Gregory Tiesi about Trans Arterial Microperfusion, or TAMP technology, and what it could mean for the future of pancreatic cancer treatment.
Trans-Arterial Micro-Perfusion Could Boost Systemic Chemotherapy Efficacy in Unresectable Pancreatic Cancer: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; and Eric Pletcher, MD
In this episode, Gregory J. Tiesi, MD, FACS, FSSO, hosted a discussion about the growing role for transarterial microperfusion (TAMP) as a regional therapy strategy for patients with locally advanced pancreatic ductal adenocarcinoma (PDAC).
New Device Delivers Targeted Chemo for Pancreatic Cancer, Offering Fresh Hope
For 70-year-old Roberta Luna, tending to her garden is therapy — especially trimming rosemary, its purple blooms matching the color she wears every day for pancreatic cancer awareness: purple.